Guan L, Townsend R, Eisenstein T K, Adler M W, Rogers T J
Department of Microbiology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140.
Brain Behav Immun. 1994 Sep;8(3):229-40. doi: 10.1006/brbi.1994.1021.
We have previously shown that antibody responses are inhibited following administration of kappa-opioid agonists. We found that the inhibition was blocked by either naloxone or the kappa-selective antagonist norbinaltorphimine. This inhibitory activity is apparent after short-term treatment with the kappa-opioid agonist. In an attempt to identify the cell populations which serve as the target for this immunosuppressive effect, we have carried out cell fractionation analyses to generate isolated T cells and macrophages. Using multiple cell fractionation methods, we have determined that short-term treatment of either T cells or macrophages with the kappa-opioid agonist U50,488H results in significant inhibition of in vitro antibody responses. We also find that the inhibition of both T cell and macrophage activity can be blocked by naloxone. These studies demonstrate that resting T cells and macrophages express kappa-opioid receptors and exhibit significant opioid responsiveness prior to activation by antigen.
我们之前已经表明，给予κ-阿片受体激动剂后抗体反应会受到抑制。我们发现，这种抑制作用可被纳洛酮或κ-选择性拮抗剂 norbinaltorphimine 阻断。在用κ-阿片受体激动剂进行短期治疗后，这种抑制活性就很明显。为了确定作为这种免疫抑制作用靶点的细胞群体，我们进行了细胞分级分离分析以获得分离的 T 细胞和巨噬细胞。使用多种细胞分级分离方法，我们确定用κ-阿片受体激动剂 U50,488H 对 T 细胞或巨噬细胞进行短期治疗会导致体外抗体反应受到显著抑制。我们还发现，纳洛酮可以阻断对 T 细胞和巨噬细胞活性的抑制。这些研究表明，静息 T 细胞和巨噬细胞表达κ-阿片受体，并且在被抗原激活之前就表现出显著的阿片样物质反应性。
